Literature DB >> 22084371

Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.

Bradley J Monk, Lini N Pandite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22084371     DOI： 10.1200/JCO.2011.38.8777

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.

Authors:  Daniela Luvero; Francesco Plotti; Salvatore Lopez; Giuseppe Scaletta; Stella Capriglione; Roberto Montera; Gianina Antonelli; Sara Ciuffreda; Raffaella Carassiti; Alice Oliveti; Roberto Angioli
Journal:  Med Oncol       Date:  2017-05-05       Impact factor: 3.064

Review 2.  Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.

Authors:  Bernd C Schmid; Martin K Oehler
Journal:  Curr Treat Options Oncol       Date:  2015-01

Review 3.  Changing paradigms in the systemic treatment of advanced cervical cancer.

Authors:  Krista S Pfaendler; Krishnansu S Tewari
Journal:  Am J Obstet Gynecol       Date:  2015-07-26       Impact factor: 8.661

Review 4.  Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

Authors:  Gloria Marquina; Aranzazu Manzano; Antonio Casado
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

5.  Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials.

Authors:  Kathryn Osann; Susie Hsieh; Edward L Nelson; Bradley J Monk; Dana Chase; David Cella; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2014-09-03       Impact factor: 5.482

6.  Systemic therapy for cervical carcinoma - current status.

Authors:  Krystyna Serkies; Jacek Jassem
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

7.  Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

Authors:  Yunhai Chuai; Ivana Rizzuto; Xia Zhang; Ying Li; Guanghai Dai; Sophie J Otter; Rasiah Bharathan; Alexandra Stewart; Aiming Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

Review 8.  New molecular targets against cervical cancer.

Authors:  Alfonso Duenas-Gonzalez; Alberto Serrano-Olvera; Lucely Cetina; Jaime Coronel
Journal:  Int J Womens Health       Date:  2014-12-05

Review 9.  Emerging biological treatments for uterine cervical carcinoma.

Authors:  Patrizia Vici; Luciano Mariani; Laura Pizzuti; Domenico Sergi; Luigi Di Lauro; Enrico Vizza; Federica Tomao; Silverio Tomao; Emanuela Mancini; Cristina Vincenzoni; Maddalena Barba; Marcello Maugeri-Saccà; Giuseppe Giovinazzo; Aldo Venuti
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

Review 10.  Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence.

Authors:  Matthew W Jackson; Chad G Rusthoven; Christine M Fisher; Tracey E Schefter
Journal:  Onco Targets Ther       Date:  2014-05-16       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.